Prophase Labs (PRPH)
OTHER OTC:PRPH
Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.18
-$0.13(-18.06%)
At close: 4:00 PM EST
$0.18
-$0.13(-18.06%)
Day’s Range― - ―
52-Week Range$0.07 - $6.66
Previous CloseN/A
Volume469.10K
Average Volume (3M)48.99K
Market Cap
$712.00K
Enterprise Value$8.88M
Total Cash (Recent Filing)$90.00K
Total Debt (Recent Filing)$8.62M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding9,493,287
10 Day Avg. Volume52,221
30 Day Avg. Volume48,994
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.43
Enterprise Value/Market Cap12.48
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit6.42
Enterprise Value/Ebitda-0.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsOperating both consumer OTC products and diagnostic laboratory services provides structural diversification of revenue drivers. This dual business model can smooth cash flow swings across channels, enable cross-selling opportunities, and reduce single-market dependency over the next several months.
Improving Profitability Trend In 2025A meaningful narrowing of losses and recovery of gross margin in 2025 indicate the company is moving toward operating stabilization. If sustained, improved margins and smaller losses reduce near-term financing pressure and increase the chance of achieving break-even within a multi-quarter horizon.
Debt Reduction In 2025The reduction in total debt during 2025 improves interest burden and provides incremental financial flexibility. Even with leverage still high, lower absolute debt reduces refinancing needs and modestly extends runway, which matters for execution over the next several quarters.
Bears Say
Sustained Negative Cash FlowMulti-year negative operating and free cash flow is a structural concern: it erodes liquidity, forces reliance on external financing or asset sales, and limits capacity to fund working capital or strategic initiatives. Continued cash burn raises dilution and refinancing risk over 2–6 months.
Elevated Leverage And Weakened Balance SheetHigher debt-to-equity and a sharp decline in equity reduce financial flexibility and increase vulnerability to revenue shocks. Elevated leverage raises interest and covenant risks, constrains capital allocation, and heightens refinancing risk if operational improvements falter in the coming quarters.
Volatile Revenue And Persistent Large LossesHigh revenue volatility coupled with continued large operating and net losses undermines predictability of cash flows and planning. This pattern hinders consistent margin expansion and raises the probability the company will need further capital if improved trends do not continue over the medium term.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.07 and its highest was $6.66 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $712.00K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Prophase Labs’s earnings last quarter?
Currently, no data Available
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 9,493,287 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
37.75%
Insiders
0.23% Mutual Funds
0.89% Other Institutional Investors
61.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---